Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

## TRADING HALT AND

## THE PUBLICATION OF THE ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022

This announcement is made by Zai Lab Limited ("Company") pursuant to Rule 13.09 of the Rules ("Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("Stock Exchange") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Trading in the shares of the Company (the "Shares") on the Stock Exchange was suspended from 9:06 a.m. on March 31, 2023 pending the publication of the annual results for the year ended December 31, 2022 (the "Annual Results"). The Annual Results were later published at around noon on the same day.

After the publication of the Annual Results, an application has been made by the Company to the Stock Exchange for the resumption of trading in the Shares on the Stock Exchange and the trading in the Shares on the Stock Exchange has been resumed at 1:00 p.m. on March 31, 2023.

By order of the Board **Zai Lab Limited Samantha Du** 

Director, Chairperson and Chief Executive Officer

Hong Kong, March 31, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W. Morrison, Richard Gaynor, M.D. and Mr. Michel Vounatsos as the independent directors.

\* For identification only